{"id":"W2726186366","doi":"10.1200/jco.2017.35.15_suppl.5002","title":"A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Clinical endpoint; Prednisone; Oncology; Urology; Gastroenterology; Cancer; Randomized controlled trial; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004193506,0.0002456238,0.002978051,0.0001357051,0.0003188285,0.00005711013,0.0002796992,0.0001557341,0.0001297664],"category_scores_gemma":[0.003638265,0.0001353428,0.0004518793,0.00007322145,0.0008284356,0.0003440004,0.00008748449,0.0005283713,0.000001341607],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002316983,"about_ca_system_score_gemma":0.002413195,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003110908,"about_ca_topic_score_gemma":0.0005214066,"domain_scores_codex":[0.9950708,0.0005375486,0.002928707,0.0003197939,0.000765377,0.0003778057],"domain_scores_gemma":[0.9911505,0.001737405,0.004320451,0.0004153465,0.001985927,0.0003903945],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8699802,0.02337867,0.07808064,0.0001523847,0.003193181,0.0002848387,0.001081665,0.00003141269,0.0003984027,0.00001513901,0.000577787,0.02282563],"study_design_scores_gemma":[0.7731149,0.1283725,0.09345243,0.0002077082,0.001979051,0.00001318697,0.0002041957,0.0001412811,0.0004390553,0.0001245183,0.001828944,0.0001222489],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935051,0.0003994187,0.00004766194,0.001496453,0.0005823314,0.003675073,0.0001318634,0.000006207163,0.0001559126],"genre_scores_gemma":[0.9956723,0.0005667402,0.001546683,0.0001488321,0.0003365984,0.0002538747,0.00001448352,0.00003317662,0.001427315],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1049938,"threshold_uncertainty_score":0.551912,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1569140365483028,"score_gpt":0.5432351185979689,"score_spread":0.3863210820496661,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}